Pure Red Cell Aplasia, Acquired
Synonyms of Pure Red Cell Aplasia, Acquired
- Pure Red Blood Cell Aplasia
- No subdivisions found.
Acquired Pure Red Cell Aplasia is a rare bone marrow disorder characterized by an isolated decline of red blood cells (erythrocytes) produced by the bone marrow. Affected individuals may experience fatigue, lethargy, and/or abnormal paleness of the skin (pallor). Acquired Pure Red Cell Aplasia may occur for unknown reasons (idiopathic) or as a primary autoimmune disorder. It is also believed that Acquired Pure Red Cell Aplasia may occur secondary to a tumor of the thymus gland (thyoma), viral infections, or certain drugs.
Acquired Pure Red Cell Aplasia is characterized by a decrease in the number of red blood cells produced in the bone marrow. Individuals with this disorder are deficient in the number of precursors of red blood cells (erythroblasts). Levels of the hormone erythropoietin that stimulates the bone marrow to produce red blood cells are usually elevated.
Affected individuals may experience fatigue, lethargy, and/or abnormal paleness of the skin (pallor).
Acquired Pure Red Cell Aplasia is thought to be an autoimmune disorder possibly caused either by a tumor of the thymus gland, certain drugs or a viral infection. It is one of a group of bone marrow failure syndromes.
Acquired Pure Red Cell Aplasia is a rare disorder affecting males and females in equal numbers.
Symptoms of the following disorders are similar to those of Acquired Pure Red Cell Aplasia. Comparisons may be useful for a differential diagnosis:
Aplastic Anemia is characterized by failure of the bone marrow to produce red blood cells, white blood cells and platelets. Certain other anemias are due either to excessive red cell destruction or a limited production of red blood cells. Aplastic Anemia may occur for unknown reasons, or it may be the result of a toxic reaction to radiation, certain drugs or chemicals. In rare cases, the disorder may be caused by a tumor in the thymus gland. (For more information on this disorder, choose "Aplastic Anemia" as your search term in the Rare Disease Database.)
Blackfan-Diamond Anemia is a very rare genetic blood disorder which is present at birth. Blood cell abnormalities accompany an unusual physical appearance, paleness, weakness, and lethargy. (For more information on this disorder, choose "Blackfan" as your search term in the Rare Disease Database.)
Fanconi's Anemia is a rare form of familial aplastic anemia. It is characterized by bone abnormalities, an abnormally small head (microcephaly), decreased functioning of the sex organs (hypogenitalism) and brown pigmentation of the skin. Complications may include infections such as pneumonia, meningitis, excessive bleeding (hemorrhages), and leukemia. Other malignancies may also occur. (For more information on this disorder, choose "Fanconi" as your search term in the Rare Disease Database.)
Acquired Pure Red Cell Aplasia usually goes into remission when certain drugs such as sulfonylureas (used for treating diabetes), gold for treatment of arthritis, penicillin, phenytoin and phenobarbitol used for treating epilepsy, or the anesthetic halothane which can cause this disorder are discontinued. In affected individuals under 30 years of age, the disorder may initially be treated with the immune suppressant drug prednisone and/or antithymocyte globulin. The drugs cyclophosphamide, azathioprine, or 6-mercaptopurine which also suppress the immune system may be used for treating older individuals with Acquired Pure Red Cell Aplasia or those who fail to respond to steroids or antithymocyte globulin. Patients in both age groups may require periodic blood transfusions until the drugs take effect. The drug treatment is slowly decreased when remission of the disorder is acheived.
If an individual with Acquired Pure Red Cell Aplasia has a tumor of the thymus gland, surgical removal of this gland often causes remission of this disorder.
Scientists are studying a number of drugs that suppress the immune system in people with Acquired Pure Red Cell Aplasia. More studies are needed to determine the long-term safety and effectivness of these treatments.
Information on current clinical trials is posted on the Internet at www.clinicaltrials.gov. All studies receiving U.S. government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
For information about clinical trials sponsored by private sources, contact:
Pure Red Cell Aplasia, Acquired Resources
NORD Member Organizations:
(To become a member of NORD, an organization must meet established criteria and be approved by the NORD Board of Directors. If you're interested in becoming a member, please contact Susan Olivo, Membership Manager, at email@example.com.)
Hematology Basic Principles and Practice, 2nd Ed.: Ronald Hoffman M.D., et. al., Editors; Churchill-Livingstone, Inc., 1995. Pp. 350-70.
Pure Red Cell Aplasia Characterized by Erythropoietic Maturation Arrest. Response to Anti-Thymocyte Globulin. A.D. Jacobs et al.; American Journal Med (Mar 1985; 78(3)). Pp. 515-17.
New Therapies for Aplastic Anemia. S.B. Krantz; American Journal Med Sciences (1986; 291). Pp. 371-79.
Diphenylhydantoin-Induced Pure Red Cell Aplasia. E.N. Dessypris et al.; Blood (1985; 65). Pp. 789-94.
Brief Report: Autoantibodies Against Erythropoietin in a Patient with Pure Red-Cell Aplasia. N. Casadevall et al.; New Eng J Med (Mar 7 1996; 334(10)). Pp. 630-33.
Successful Treatment of a Patient with a Thymoma and Pure Red-Cell Aplasia with Octreotide and Prednisone. G. Palmieri et al.; New Eng J Med (Jan 23 1997; 336(4)). Pp. 263-65.
Acquired Pure Red Cell Aplasia in Japan. S. Mamiya et al.; Eur J Haematol (Oct 1997; 59(4)). Pp. 199-205.
The information in NORD’s Rare Disease Database is for educational purposes only. It should never be used for diagnostic or treatment purposes. If you have questions regarding a medical condition, always seek the advice of your physician or other qualified health professional. NORD’s reports provide a brief overview of rare diseases. For more specific information, we encourage you to contact your personal physician or the agencies listed as “Resources” on this report.
The National Organization for Rare Disorders (NORD) web site, its databases, and the contents thereof are copyrighted by NORD. No part of the NORD web site, databases, or the contents may be copied in any way, including but not limited to the following: electronically downloading, storing in a retrieval system, or redistributing for any commercial purposes without the express written permission of NORD. Permission is hereby granted to print one hard copy of the information on an individual disease for your personal use, provided that such content is in no way modified, and the credit for the source (NORD) and NORD’s copyright notice are included on the printed copy. Any other electronic reproduction or other printed versions is strictly prohibited.
Copyright ©1988, 1989, 1996, 1997, 1999, 2007
Report last updated: 2007/08/07 00:00:00 GMT+0
NORD's Rare Disease Information Database is copyrighted and may not be published without the written consent of NORD.